Law360, New York (January 03, 2012, 1:15 PM ET) -- Merck Canada Inc. on Thursday sued Mylan Pharmaceuticals Inc. in New Jersey federal court for allegedly infringing a Merck patent when it sought U.S. Food and Drug Administration approval for a generic version of the asthma treatment Singulair.
The plaintiffs — Merck Canada, Merck Frosst Canada & Co. and Merck Sharp & Dohme Pharmaceuticals — say Mylan alerted them in a Nov. 15 letter that it had lodged an abbreviated new drug application seeking a green light to make and sell its generic.
Mylan also informed...
Merck Canada Sues To Block Mylan's Generic Singulair
To view the full article, take a free trial now.
